PHOENIX BIOTECHNOLOGY, INC. Patent applications |
Patent application number | Title | Published |
20150316550 | Method of Determining the Probability of a Therapeutic Response in Cancer Chemotherapy with Cardiac Glycoside - A prognostic assay and kit and method of use thereof are provided. The kit and assay are used to determine the likelihood of a diseased cell or tissue having a therapeutic response to treatment with a cardiac glycoside in a disease having an etiology associated with excessive cell proliferation. The kit and assay are used to determine the ratio of isoforms of the α subunit of Na, K-ATPase obtained from the diseased cell or tissue. The kit can be used to predict the therapeutic responsiveness of cancer or tumor in a subject to treatment with a cardiac glycoside. The kit and assay can be incorporated in a method of treating a disease or disorder having an etiology associated with excessive cell proliferation with a composition comprising a cardiac glycoside. | 11-05-2015 |
20150283191 | Method of Treating Neurological Conditions with Extract of Nerium Species or Thevetia Species - A method of treating neurological condition in a subject by administration of an extract, or fraction or sub-fraction thereof, of | 10-08-2015 |
20130324485 | Method of Determining the Probability of a Therapeutic Response in Cancer Chemotherapy with Cardiac Glycoside - A prognostic assay and kit and method of use thereof are provided. The kit and assay are used to determine the likelihood of a diseased cell or tissue having a therapeutic response to treatment with a cardiac glycoside in a disease having an etiology associated with excessive cell proliferation. The kit and assay are used to determine the ratio of isoforms of the α subunit of Na, K-ATPase obtained from the diseased cell or tissue. The kit can be used to predict the therapeutic responsiveness of cancer or tumor in a subject to treatment with a cardiac glycoside. The kit and assay can be incorporated in a method of treating a disease or disorder having an etiology associated with excessive cell proliferation with a composition comprising a cardiac glycoside. | 12-05-2013 |
20120219620 | SCF Extract Containing Cardiac Glycoside - A supercritical fluid (SCF) extract of a cardiac glycoside-containing plant mass is provided. The extract can be included in a pharmaceutical composition containing an extract-solubilizing amount of solubilizer. Oleandrin is included within the extract when a cardiac glycoside-containing plant, such as | 08-30-2012 |
20120128798 | Method of Treating Neurological Conditions with Extract of Nerium Species or Thevetia Species - A method of treating neurological condition in a subject by administration of an extract, or fraction or sub-fraction thereof, of | 05-24-2012 |
20110172172 | Method of Treating Neurological Conditions with Cardiac Glycoside - A method of treating neurological condition in a subject by administration of a cardiac glycoside is provided. Alzheimer's disease, Huntington's disease or stroke are treated by administering a therapeutically effective amount of cardiac glycoside to a subject. The cardiac glycoside can be present in a dosage form. | 07-14-2011 |
20100317541 | Method of Determining the Probability of a Therapeutic Response in Cancer Chemotherapy With Cardiac Glycoside - A prognostic assay and kit and method of use thereof are provided. The kit and assay are used to determine the likelihood of a diseased cell or tissue having a therapeutic response to treatment with a cardiac glycoside in a disease having an etiology associated with excessive cell proliferation. The kit and assay are used to determine the ratio of isoforms of the α subunit of Na, K-ATPase obtained from the diseased cell or tissue. The kit can be used to predict the therapeutic responsiveness of cancer or tumor in a subject to treatment with a cardiac glycoside. The kit and assay can be incorporated in a method of treating a disease or disorder having an etiology associated with excessive cell proliferation with a composition comprising a cardiac glycoside. | 12-16-2010 |
20080200401 | SCF Extract Containing Cardiac Glycoside - A supercritical fluid (SCF) extract of a cardiac glycoside-containing plant mass is provided. The extract can be included in a pharmaceutical composition containing an extract-solubilizing amount of solubilizer. Oleandrin is included within the extract when a cardiac glycoside-containing plant, such as | 08-21-2008 |